FindTrial
Sign In

MM-121

DRUG10 trials

Sponsors

Merrimack Pharmaceuticals, Elevation Oncology

Conditions

AdenocarcinomaAdvanced Solid TumorsCarcinoma, Non-Small-Cell LungColorectal CancerER Positive, Her2 Negative Breast Cancer PatientsEpithelial Ovarian CancerFallopian Tube CancerHer2 Negative Breast Cancer Patients

Phase 1

Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment
CompletedNCT00734305
Merrimack PharmaceuticalsAdvanced Solid Tumors
Start: 2008-07-31End: 2013-09-30Updated: 2016-09-01
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
CompletedNCT00994123
Merrimack PharmaceuticalsCarcinoma, Non-Small-Cell Lung
Start: 2010-02-28End: 2015-06-30Updated: 2016-08-22
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
CompletedNCT01209195
Merrimack PharmaceuticalsLocally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer, Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
Start: 2010-10-31End: 2014-07-31Updated: 2016-09-08
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
CompletedNCT01447225
Merrimack PharmaceuticalsSolid Tumors
Start: 2011-10-31End: 2014-01-31Updated: 2016-09-14
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
CompletedNCT01451632
Merrimack PharmaceuticalsColorectal Cancer, Non-small Cell Lung Cancer, Other Tumors With EGFR Dependence +2
Start: 2011-10-31End: 2014-06-30Updated: 2016-09-08
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
TerminatedNCT02538627
Merrimack PharmaceuticalsColorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Start: 2015-08-31End: 2016-10-05Updated: 2017-09-05

Phase 2

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
CompletedNCT01151046
Merrimack PharmaceuticalsHer2 Negative Breast Cancer Patients
Start: 2010-06-30End: 2014-09-30Updated: 2016-05-12
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
CompletedNCT01421472
Merrimack PharmaceuticalsER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
Start: 2011-08-31End: 2014-06-30Updated: 2016-05-03
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
CompletedNCT01447706
Merrimack PharmaceuticalsEpithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Start: 2011-10-31End: 2015-06-30Updated: 2016-05-12
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
TerminatedNCT02387216
Elevation OncologyAdenocarcinoma, Heregulin, Non-Small Cell Lung Cancer +1
Start: 2015-02-01End: 2019-01-02Updated: 2021-10-12

Related Papers

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors
Investigational New Drugs2021-07-1128 citations
SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2019-05-209 citations
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
The Oncologist2019-04-1153 citations
A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2016-05-203 citations
A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.
Journal of Clinical Oncology2016-05-201 citations
A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.
Journal of Clinical Oncology2014-05-2032 citations
A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.
Journal of Clinical Oncology2014-05-2029 citations
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers.
Journal of Clinical Oncology2014-05-2018 citations
A phase 1 study of MM-121 (a fully human monoclonal antibody targeting the epidermal growth factor receptor family member ErbB3) in combination with cetuximab and irinotecan in patients with advanced cancers.
Journal of Clinical Oncology2014-05-2013 citations